Actively Recruiting
Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease
Led by University of Sao Paulo · Updated on 2026-05-07
40
Participants Needed
1
Research Sites
714 weeks
Total Duration
On this page
Sponsors
U
University of Sao Paulo
Lead Sponsor
F
Fundação de Amparo à Pesquisa do Estado de São Paulo
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective study will include patients with Vogt-Koyanagi-Harada disease from disease onset, treated with early systemic high-dose corticosteroid and immunosuppressive therapy. Clinical and subclinical signs of disease activity added with electroretinogram exams, through predefined intervals, will be evaluated through a minimum 12-month follow-up.
CONDITIONS
Official Title
Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Acute Vogt-Koyanagi-Harada disease
You will not qualify if you...
- Non-collaborative patient
- Patients with less than one-year follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital das Clinicas HCFMUSP, Faculdade de Medicina Universidade de Sao Paulo
São Paulo, São Paulo, Brazil, 05403-000
Actively Recruiting
Research Team
J
Joyce H Yamamoto, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here